Investigational Drug, MW-III: Topical application, twice a day
Silvadene® Cream 1% [Silver Sulfadiazine]: Topical application, twice a day
Study summary
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Adults, 18 years of age or older on the day of signing the informed consent.
2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
3. Able and willing to give informed consent and comply with study procedures.
Exclusion Criteria:
1. Any burn that at screening is:
1. infected.
2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
2. Severe inhalation injury or other significant non-burn trauma.
Primary outcome measure(s)
Time to healing (≥95% re-epithelialization) of the partial thickness target burn. — 28 days Treatment Period Time to healing (≥95% re-epithelialization) of the partial thickness target burn.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.